Supernus Pharmaceuticals Inc (SUPN) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.

Total Cash From Operating Activities Chart for Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc (SUPN) operating cash flow for FY2025 was USD 47.3M, a -72.5% change from FY2024. Supernus Pharmaceuticals Inc's operating cash flow moved from USD -14.0M in 2007 to USD 47.3M in 2025 over 18 years. Operating cash flow compound annual growth rate: 5-year CAGR of -19.3%, 10-year CAGR of 4.0%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$2.21B
Implied Share Price
$37.88
Enterprise Value
$2.19B
Revenue (TTM)
$830.44M
EBITDA
$110.43M
Profit Margin
-13.23%
Trailing P/E
—
Forward P/E
20.16
Price/Book (MRQ)
2.45
Price/Sales (TTM)
2.66
EV/EBITDA
51.86
EV/Revenue
2.64
Dividend Yield
—
Book Value
$17.73
Free Cash Flow (FY2025)
$45.99M
Free Cash Flow Yield
2.09%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.